A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Gantrisin Indications, Dosage, Storage, Stability - Acetyl Sulfisoxazole
Gantrisin Indications, Dosage, Storage, Stability - Acetyl Sulfisoxazole
INDICATIONS
Acute, recurrent or chronic
urinary tract
infections (primarily pyelonephritis, pyelitis and cystitis) due to susceptible
organisms (usually Escherichia coli, Klebsiella-Enterobacter, staphylococcus,
Proteus mirabilis and,
less frequently, Proteus vulgaris) in the absence
of obstructive uropathy or foreign bodies.
Meningococcal meningitis
where the organism has been
demonstrated to be susceptible. Haemophilus influenzae meningitis
as adjunctive therapy with parenteral
streptomycin.
Meningococcal meningitis
prophylaxis when sulfonamide-sensitive
group A strains are known to prevail in family
groups or larger closed populations. (The prophylactic
usefulness of sulfonamides when group
B or C infections are prevalent has not been proven and in closed population
groups may be harmful.)
Acute otitis media
due to Haemophilus influenzae when used concomitantly with adequate
doses of penicillin or
erythromycin (see appropriate
labeling for prescribing information).
Trachoma. Inclusion conjunctivitis. Nocardiosis. Chancroid. Toxoplasmosis
as adjunctive therapy with
pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium
falciparum, when used as adjunctive therapy.
Currently, the increasing frequency
of resistant organisms is a limitation of the usefulness of antibacterial
agents including the sulfonamides, especially in the treatment
of chronic and recurrent urinary
tract infections.
Important Note: In vitro sulfonamide susceptibility
tests are not always reliable. The test
must be carefully coordinated with bacteriologic and clinical
response. When the patient
is already taking sulfonamides, follow-up cultures should have aminobenzoic
acid added to the culture
media.
DOSAGE AND ADMINISTRATION
Systemic sulfonamides are contraindicated in infants less than 2 months
of age, except in the treatment
of congenital toxoplasmosis
as adjunctive therapy with pyrimethamine.
Usual Dose for Pediatric Patients Over 2 Months of Age
Initial dose: One half of the 24-hour dose.
Maintenance dose: 150 mg/kg/24 hours or 4 gm/M²/24
hours — dose to be divided into
4 to 6 doses/24 hours. The maximum
dose should not exceed 6 gm/24 hours.
HOW SUPPLIED
Pediatric Suspension (raspberry flavored), containing acetyl
sulfisoxazole equivalent to approximately 0.5 gm sulfisoxazole
per teaspoonful (5 mL) — bottles
of 16 o (1 pint) (NDC 0004-1003-28).
REFERENCES
1 . Boisvert A, Barbeau G, Belanger PM. Pharmacokinetics
of sulfisoxazole in
young and elderly subjects. Gerontology. 1984, 30: 125-131.
2. Oie S, Gambertoglio JG, Fleckenstein L. Comparison of
the disposition of total
and unbound sulfisoxazole
after single and multiple dosing. J Pharmacokinet Biopharm. 1982; 10:
157-172.
3. National Committee for Clinical Laboratory Standards.
Performance Standards for Antimicrobial Disk Susceptibility Tests. 4th
ed. Villanova, PA: April 1990. Approved Standard NCCLS Document M2-A4,
Vol . 10, No. 7 NCCLS.
4. National Committee for Clinical Laboratory Standards.
Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that
Grow Aerobically. 2nd ed. Villanova, PA: April 1990. Approved Standard
NCCLS Document M7-A2, Vol. 10, No. 8 NCCLS.
top
